163 related articles for article (PubMed ID: 34603481)
21.
Wang L; Yan K; He X; Zhu H; Song J; Chen S; Cai S; Zhao Y; Wang L
J Cancer; 2021; 12(1):217-223. PubMed ID: 33391418
[No Abstract] [Full Text] [Related]
22. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
23. Association of
Chen H; Chong W; Wu Q; Yao Y; Mao M; Wang X
Front Immunol; 2019; 10():1113. PubMed ID: 31164891
[No Abstract] [Full Text] [Related]
24. Integrative analysis of the proteome and transcriptome in gastric cancer identified LRP1B as a potential biomarker.
Miao J; Yang Z; Guo W; Liu L; Song P; Ding C; Guan W
Biomark Med; 2022 Oct; 16(15):1101-1111. PubMed ID: 36606427
[No Abstract] [Full Text] [Related]
25. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
26. Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response.
Hao F; Ma Q; Zhong D
Transl Oncol; 2022 Oct; 24():101493. PubMed ID: 35905642
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
28. Clonal Architectures Predict Clinical Outcome in Gastric Adenocarcinoma Based on Genomic Variation, Tumor Evolution, and Heterogeneity.
Ren C; Wu C; Wang N; Lian C; Yang C
Cell Transplant; 2021; 30():963689721989606. PubMed ID: 33900127
[TBL] [Abstract][Full Text] [Related]
29. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
30. Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer.
Li W; Zhou K; Li M; Hu Q; Wei W; Liu L; Zhao Q
BMC Gastroenterol; 2022 Feb; 22(1):45. PubMed ID: 35123417
[TBL] [Abstract][Full Text] [Related]
31. Identifying Diagnostic and Prognostic Biomarkers and Candidate Therapeutic Drugs of Gastric Cancer Based on Transcriptomics and Single-Cell Sequencing.
Zhao X; Wu S; Jing J
Pathol Oncol Res; 2021; 27():1609955. PubMed ID: 34899080
[No Abstract] [Full Text] [Related]
32. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
33. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract][Full Text] [Related]
34. Near-Comprehensive Resequencing of Cancer-Associated Genes in Surgically Resected Metastatic Liver Tumors of Gastric Cancer.
Ikari N; Serizawa A; Mitani S; Yamamoto M; Furukawa T
Am J Pathol; 2019 Apr; 189(4):784-796. PubMed ID: 30703342
[TBL] [Abstract][Full Text] [Related]
35. Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden.
Chen Z; Cheng G
Recent Pat Anticancer Drug Discov; 2023 Sep; ():. PubMed ID: 37691229
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
37. MUC16 mutation predicts a favorable clinical outcome and correlates decreased Warburg effect in gastric cancer.
Zhao H; Zhang L
Biochem Biophys Res Commun; 2018 Dec; 506(4):780-786. PubMed ID: 30389134
[TBL] [Abstract][Full Text] [Related]
38. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
39. Construction and Evaluation of a Tumor Mutation Burden-Related Prognostic Signature for Thyroid Carcinoma.
Lu H; Liu Q; Chang Q; Du J; Zhang C; Chang W; Guo X; Hu Y; Liu S; Tang G; Chen C
Comput Math Methods Med; 2021; 2021():1435827. PubMed ID: 34697553
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Implications of LRP1B and Its Relationship with the Tumor-Infiltrating Immune Cells in Gastric Cancer.
Wang R; Zhang G; Zhu X; Xu Y; Cao N; Li Z; Han C; Qin M; Shen Y; Dong J; Ma F; Zhao A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
